The current study demonstrates across three cognitive domains, that acute responses to low doses of LSD depend on the baseline state and provides some support for LSD induced neuroadaptations that sustain beyond treatment.

These findings suggest that an acute low dose of LSD (26 µg) elicits more pronounced positive mood and stimulant-like effects, as well as stronger altered states of consciousness in individuals with depressive symptoms, compared to non-depressed individuals.

We conclude that VHD is a potential risk with chronic psychedelic microdosing, but further studies are necessary to better define this risk.

Trait mindfulness, specifically description and non-judging of inner experience, was increased, and neuroticism was decreased after 4  weeks of MD compared to baseline. The remaining personality traits remained unchanged. Using conventional medication and/or having comorbid diagnoses did not change the MD-induced effects on mindfulness and personality traits after 4  weeks. Conclusion: MD induced changes in otherwise stable traits. Future placebo-controlled studies are warranted to confirm whether these changes occur in a controlled setting.

These results establish a well-validated regimen for further experiments probing the effects of repeated low doses of psilocybin. Results further substantiate anecdotal reports of the benefits of psilocybin microdosing as a therapeutic intervention, while pointing to a possible physiological mechanism.

All those (phase 3) studies have one or two doses of psilocybin. If I were a betting man, I would say there’s little chance that that type of dosing would be an issue, but we still need to do clinical trials. The big concern is with repeated dosing, and lots of people are doing that now with microdosing. That’s extraordinarily risky until the appropriate studies have been done.

The purpose of this paper is to present a review of studies (double-blind, longitudinal, open, randomized and controlled trials [mostly with placebo]) on the use of microdosing with hallucinogens that combine psychotherapeutic techniques with administrations of LSD, MDMA or psilocybin.

We propose that feeling and behaving authentically could have a central role in explaining the positive effects of microdosing on health and wellbeing that are reported by current research.

Daily questionnaires showed credible evidence (>99% posterior probability) of improved ratings of creativity, connectedness, energy, happiness, irritability, and wellness